摘要
目的:评价吉非替尼门诊治疗晚期非小细胞肺癌的疗效及毒副反应。方法:对72例化疗失败或不能耐受化疗及不愿接受化疗的经病理或细胞学证实的晚期NSCLC患者给予吉非替尼250 mg,口服,qd,至病情进展或出现不可耐受的不良反应。结果:72例患者中无完全缓解患者,部分缓解25例(34.7%),稳定18例(25.0%),疾病控制率59.7%,进展29例(40.3%)。中位肿瘤进展时间(TTP)为7.0个月,1年生存率为52.7%。与药物相关的不良反应依次为痤疮样皮疹34例(47.2%),皮肤干燥21例(29.2%),腹泻19例(26.4%),恶心9例(12.5%),肝功能异常(ALT,AST升高)3例(4.2%)。结论:吉非替尼门诊治疗晚期NSCLC安全有效,毒副反应轻微,患者耐受性和依从性好。
Objective：To evaluate the efficacy and safety of gefitinib （Iressa, ZD1839） in outpatients with advanced non-small cell lung cancer （NSCLC）. Methods： The outpatients with advanced non-small cell lung cancer（n = 72） had faild, or not tolerated, or refused to chemotherapy. They were given with 250 mg of oral gefitinib once daily until disease was progressed or toxicities were not tolerated by the patients. Results： In all the patients, no complete regression was observed; partial response （PR） rate was 34.7% （25/72） ; stable disease （SD） 25.0% （ 18/72 ） ; disease control rate （ CR ＋ PR ＋ SD） 59.7 % ; progression of disease （PD） 40.3 % （29/72） ; median time to tumor progression（TTP） was 7.0 months. One-year survival rate was 52.7%. The drug-related adverse reactions were skin rash （47.2% , 34/72） , dry skin （29.2% , 21/72）, diarrhea （26.4% , 19/72）, nausea （ 12.5%, 9/72）, and hepatic dysfunction （ALT and AST increase, 4.2% , 3/72）. Conclusion： Gefitinib is active and safe in outpatients with NSCLC. It is well tolerated with minimal side-effects. All outpatients have better compliance and tolerability.
出处
《中国新药杂志》
CAS
CSCD
北大核心
2009年第2期136-138,141,共4页
Chinese Journal of New Drugs
关键词
吉非替尼
非小细胞肺癌
门诊患者
gefitinib
NSCLC （non-small cell lung cancer）
outpatient
